On the stock market since 2020, it operates in the world of health and science. It has 33 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $11.4M a year. A small number, but proof the product has real buyers.
There is $13.9M in the vault; even if every debt were paid off, $13.9M would remain.
Over the last 12 months, company executives reported 2 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $6.3M against $11.4M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
On our five-subject report card, ZCMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ZCMD is a high-risk stock — not yet profitable, and its future rides on its product catching on.